Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

Grande, Carlos; Quintero, Guillermo; Candamio, Sonia; Bouzas, L. París; Villanueva, María José; Campos, Begoña; Gallardo, Elena; Álvarez, Elena; Casal, J.; Mel, J. R.

doi:10.1016/j.jgo.2013.01.001

Cited by 15 publications

(13 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, as opposed to some large registry-based studies, which might lack important data, we extracted very detailed clinical data from the patients’ individual medical files. Third, in contrast to other studies evaluating elderly patients with CRC which included much lower age cut-off[ 9 , 10 , 12 , 13 , 19 , 27 , 34 , 38 ], this study’s cut-off probably might highlighted the differences between older and the younger population better.…”

Section: Discussionmentioning

confidence: 81%

“…Consistent with earlier studies[ 7 - 9 ], octogenarians in our cohort had worse outcome. Nonetheless, as other studies have indicated similar outcomes across different age groups[ 10 - 13 ], the actual impact of age on the outcome of the disease still remains to be established.…”

Section: Discussionmentioning

confidence: 94%

“…Currently, the impact of older age on tumor biology and outcome remains unclear. While some studies imply that elderly patients with CRC might have unique features[ 5 - 7 ] as well as worse outcome[ 7 - 9 ], these findings are not consistent[ 10 - 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity

Goldvaser

Shroitman

Ben‐Aharon

et al. 2017

WJG

View full text Add to dashboard Cite

AIMTo characterize colorectal cancer (CRC) in octogenarians as compared with younger patients.METHODSA single-center, retrospective cohort study which included patients diagnosed with CRC at the age of 80 years or older between 2008-2013. A control group included consecutive patients younger than 80 years diagnosed with CRC during the same period. Clinicopathological characteristics, treatment and outcome were compared between the groups. Fisher’s exact test was used for dichotomous variables and χ2 was used for variables with more than two categories. Overall survival was assessed by Kaplan-Meier survival analysis, with the log-rank test. Cancer specific survival (CSS) and disease-free survival were assessed by the Cox proportional hazards model, with the Fine and Gray correction for non-cancer death as a competing risk.RESULTSThe study included 350 patients, 175 patients in each group. Median follow-up was 40.2 mo (range 1.8-97.5). Several significant differences were noted. Octogenarians had a higher proportion of Ashkenazi ethnicity (64.8% vs 47.9%, P < 0.001), a higher rate of personal history of other malignancies (22.4% vs 13.7%, P = 0.035) and lower rates of family history of any cancer (36.6% vs 64.6%, P < 0.001) and family history of CRC (14.4% vs 27.3%, P = 0.006). CRC diagnosis by screening was less frequent in octogenarians (5.7% vs 20%, P < 0.001) and presentation with performance status (PS) of 0-1 was less common in octogenarians (71% vs 93.9%, P < 0.001). Octogenarians were more likely to have tumors located in the right colon (45.7% vs 34.3%, P = 0.029) and had a lower prevalence of well differentiated histology (10.4% vs 19.3%, P = 0.025). They received less treatment and treatment was less aggressive, both in patients with metastatic and non-metastatic disease, regardless of PS. Their 5-year CSS was worse (63.4% vs 77.6%, P = 0.009), both for metastatic (21% vs 43%, P = 0.03) and for non-metastatic disease (76% vs 88%, P = 0.028).CONCLUSIONOctogenarians presented with several distinct characteristics and had worse outcome. Further research is warranted to better define this growing population.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity

Goldvaser

Shroitman

Ben‐Aharon

et al. 2017

WJG

View full text Add to dashboard Cite

show abstract

“…Second, as opposed to some large registrybased studies, which might lack important data, we extracted very detailed clinical data from the patients' individual medical files. Third, in contrast to other studies evaluating elderly patients with CRC which included much lower age cutoff [9,10,12,13,19,27,34,38] , this study's cutoff probably might highlighted the differences between older and the younger population better.…”

Section: Discussionmentioning

confidence: 77%

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity.

Goldvaser¹,

Shroitman

Ben‐Aharon

et al. 2017

JCO

View full text Add to dashboard Cite

show abstract

“…Oteracil potassium, a competitive inhibitor of orotate phosphoribosyltransferase, inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the serious gastrointestinal toxicity associated with 5-FU. S-1 shows broad activity against a variety of tumors and is currently approved in Japan for use in patients with non-smallcell lung cancer, gastric cancer, colorectal cancer, breast cancer, head and neck cancer, biliary tract cancer and pancreatic cancer (8)(9)(10)(11)(12)(13)(14).…”

Section: Introduction Introductionmentioning

confidence: 99%

A Phase II Study of S-1 in Elderly Patients with Unresectable Pancreatic Cancer

Kuriyama¹,

Inamori²,

Iida³

et al. 2018

SGO

View full text Add to dashboard Cite

Background/Aims: The aim of this study was to investigate the efficacy and safetyof the oral fluoropyrimidine derivativeS-1 in elderly patients with unresectable pancreatic cancer. Methods: Patients were eligible if they were at least 70 years old and had unresectable pancreatic carcinoma. S-1 was administered orally twice daily after meals at doses of 80, 100, and 120 mg/day forbody surface areasfor 28 consecutive days, followed by a 14-day rest period. Administration was repeated until the appearance of disease progression or unacceptable toxicity. Results: Twenty-one patients were enrolledin this study. Five patients (23.8%) achieved a partial response (95% CI, 8.2-47.2%),stable disease was observed in 9 patients (42.9%), and progressive disease was observed in 5 patients (23.8%).The disease control rate was 66.7%. The median time to progression and overall survivaltime were 3.7 months (95% CI, 2.3-6.5 months) and 7.3 months (95% confidence interval, 4.9-12.1 months), respectively. Toxicity was generally mild, and the most common grade 3/4 toxicities were neutro-penia (14.3%), anemia (14.3%), leucopenia (9.5%), thrombocytopenia (9.5%), anorexia (9.5%), and diarrhea (9.5%). There were no treatment-related deaths. Conclusions: Monotherapy with S-1 is an effective and well-tolerated regimen for elderly patients with unresectable pancreatic cancer.

show abstract

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

Cited by 15 publications

References 37 publications

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity.

A Phase II Study of S-1 in Elderly Patients with Unresectable Pancreatic Cancer

Contact Info

Product

Resources

About